Accustem Sciences Inc

ACUT.PK

$0.30

Closing

▲7.00%

1D

▼-52.80%

YTD

Market cap

$3.35M

52 week high

$1.95

52 week low

$0.27

Volume

140

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$3.35M

Analysts' Rating

-

Price Target (Mean)

0.00

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

-

52 week high

$1.95

52 week low

$0.27

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company’s product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company offers ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company’s wholly owned subsidiary is StemPrintER Sciences Limited.